The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura ...

Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its ...

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which ...

For people diagnosed with ocular melanomas, the only effective treatment for many years has been radiation therapy which destroys sight in the affected eye. This was Melody Burchett’s experience when ...

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 ...